-
SynerK Achieves Milestone with First Patient Dosing in Phase I siRNA Clinical Trial
•
SynerK, a developer of RNA-targeted therapies with operations in Boston, US, and Beijing and Suzhou, China, has announced the completion of first patient dosing in its Phase I clinical study for an investigational small interfering RNA (siRNA). This marks the first time such a therapy has entered the clinical phase…
-
CSPC Pharmaceutical Group Reports 11% YOY Revenue Growth in 2022 Financial Results
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has released its 2022 financial report, recording RMB 30.937 billion (USD 4.469 billion) in revenues, marking an 11% year-on-year (YOY) increase. The report details the performance of various business segments, with on-patent medicines generating RMB 24.52 billion (USD 3.5 billion, +10.8%), raw material…
-
Roche’s Q1 2023 Report: 3% Dip in Revenues with Strong Growth in Pharmaceuticals
•
Roche (SWX: ROG), the Swiss pharmaceutical and diagnostics giant, reported a 3% year-on-year (YOY) decrease in turnover at constant exchange rates (CER) to CHF 15.3 billion (USD 17.2 billion) in its Q1 2023 report. The decline was attributed to the appreciation of the Swiss franc and a predicted drop in…
-
GSK Reports Q1 2023 Revenue Dip Amid COVID-19 Treatment Decline, Underlying Growth
•
UK-based multinational GlaxoSmithKline plc (GSK, NYSE: GSK) has released its financial results for the first quarter of 2023, showing an 8% year-on-year (YOY) decrease in revenues in constant currency terms to GBP 6.95 billion (USD 8.67 billion). The decline is attributed to reduced demand for COVID-19 treatments, most notably the…
-
SinoMab’s SM03 Meets Primary Endpoint in Phase III Rheumatoid Arthritis Trial
•
Hong Kong-based biopharmaceutical company SinoMab BioScience Ltd (HKG: 3681) has announced that its Phase III clinical study for the CD22 monoclonal antibody (mAb) SM03, also known as suciraslimab, has successfully reached the primary endpoint in patients with rheumatoid arthritis (RA). Study Design and Efficacy of SuciraslimabThe randomized, double-blind, multi-center, placebo-controlled…
-
Junshi Biosciences’ RENOTORCH Study Meets Endpoints for RCC Treatment
•
Junshi Biosciences (HKG: 1877, SHA: 688180), a China-based biopharmaceutical company, has announced that its multi-center, randomized, open, positive-controlled Phase III RENOTORCH study has reached pre-set endpoints at the interim analysis stage. The study evaluates the programmed death-1 (PD-1) inhibitor Tuoyi (toripalimab) combined with axitinib for the treatment of moderate to…
-
Sihuan Pharmaceutical’s Birociclib Meets Primary Endpoint in Phase III Breast Cancer Study
•
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that its Phase III clinical study for birociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, has successfully reached the primary endpoint in patients with HR+/HER2- advanced breast cancer that has progressed after previous endocrine therapy combined with fulvestrant. Positive Mid-Term Analysis…
-
MicroPort Scientific Corp. Reports 8% Revenue Growth and Increased R&D Investment in 2022
•
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has released its 2022 annual financial report, showing an 8% year-on-year (YOY) increase in revenue to USD 840.8 million, which represents a 15.6% increase when excluding foreign exchange impact. Despite reporting a net loss of USD 588 million, up from a…
